<DOC>
	<DOCNO>NCT00988143</DOCNO>
	<brief_summary>The purpose study describe immunogenicity prototype Quadrivalent Influenza Vaccine ( QIV ) compare 2009-2010 Trivalent Influenza Vaccine ( TIV ) 2008-2009 TIV among child adult . Primary Objective : To describe immunogenicity prototype Quadrivalent Influenza Vaccine ( QIV ) compare 2009-2010 Trivalent Influenza Vaccine ( TIV ) 2008-2009 TIV among adult . Observational Objectives : - To describe safety 2009-2010 TIV among subject ≥6 month &lt; 5 year , 18-60 year , ≥ 61 year age , describe safety 2008-2009 TIV prototype QIV Fluzone® vaccine among subject 18-60 year ≥ 61 year age . - To describe immunogenicity 2009-2010 TIV vaccine among subject ≥6 month &lt; 5 year , 18-60 year , ≥61 year age , describe immunogenicity 2008-2009 TIV prototype QIV vaccine among subject 18-60 year ≥61 year age .</brief_summary>
	<brief_title>A Study Influenza Virus Vaccines Children Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Subject ≥ 6 month &lt; 5 year age 18 year age old day inclusion . Parent/legal guardian ( subject ≥ 6 month &lt; 5 year age ) adult subject ( 18 year age old ) willing able attend schedule visit comply study procedure entire duration study . Subject reasonably good health assess Investigator . Parent/legal guardian ( subject ≥ 6 month &lt; 5 year age ) adult subject ( 18 year age old ) willing able give inform consent . For subject ≥ 6 month &lt; 5 year age : subject bear full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg ( 5.5 lb ) . For woman , inability bear child negative serum/urine pregnancy test , applicable . Exclusion Criteria : For subject : History allergy egg protein , chicken protein , one constituent vaccine , thimerosal formaldehyde . History serious adverse reaction influenza vaccine . Laboratoryconfirmed influenza infection vaccination influenza six month precede enrollment study . Any vaccination schedule Visit 1 Visit 2 Visit 3 . Participation interventional drug vaccine trial participation study . Thrombocytopenia bleed disorder contraindicate intramuscular vaccination . Any condition opinion Investigator would pose health risk subject enrol could interfere evaluation vaccine . Prior personal history GuillainBarré syndrome . For subject &gt; 6 month &lt; 5 year age : Known suspected impairment immunologic function receipt immunosuppressive therapy immunoglobulin since birth . Personal immediate family history congenital immune deficiency . Developmental delay , neurologic disorder , seizure disorder . Chronic medical , congenital , developmental disorder . Known HIVpositive mother . For subject 18 year age older : Immunocompromising condition ; immunosuppressive therapy ( include systemic steroid use two week ) ; cancer chemotherapy radiation therapy time enrollment , plan period study , time within past six month . Diabetes mellitus require pharmacological control . Person deprive freedom administrative court order ( legal medical guardian ) . For woman childbearing potential , positive urine pregnancy test , breast feeding , use medically approve reliable form contraception ( oral contraceptive double barrier method ) duration trial . Current use alcohol recreational drug may interfere subject 's ability comply trial procedure . Any subject following condition eligible enrollment . However , subject may enrol subsequently condition resolve enrollment still ongoing subject meet inclusion/exclusion criterion : An acute illness without fever 72 hour precede enrollment trial . Clinically significant finding vital sign review system ( Investigator judgment ) . Received vaccination within precede 14 day . Participation interventional clinical trial within 30 day prior enrollment . Receipt blood blood product within three month precede enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Trivalent Influenza Virus Vaccine</keyword>
	<keyword>Quadrivalent Influenza Virus Vaccine</keyword>
</DOC>